Lung Cancer

The Lung Group aims to oversee, support and bring together the viewpoints of all of the multi-disciplinary teams working in lung cancer services across the Network. The group also aims to ensure the same standard of care and treatment for patients with this type of cancer across the Network.

The Group Lead is: Dr Anny Sykes, Consultant Respiratory Medicine, Oxford University Hospitals Foundation Trust.

The date for the next Lung meeting is Thursday 17th January 2019, 14:00 – 16:00, Location TBC

Protocols and Guidelines for Lung are listed below:

Whilst every effort is made to ensure the accuracy of the information in a given regimen it cannot be guaranteed that the regimen is fully up to date, because of the dynamic nature of cancer treatment.

 

Afatinib

Alectinib

Atezolizumab 28 day – Covid 19

Atezolizumab Bevacizumab Paclitaxel Carboplatin

Atezolizumab Carboplatin Etoposide

Atezolizumab

Brigatinib

Carboplatin Etoposide

Carboplatin Paclitaxel – Covid 19

CAV

Ceritinib

Cisplatin (40) with concurrent RT

Cisplatin Etoposide with concurrent RT (NSCLC)

Cisplatin Etoposide with concurrent RT (SCLC)

Crizotinib

Dacomitinib

Docetaxel

Durvalumab 28 day Covid 19

Durvalumab

Erlotinib

Gefitinib

Gemcitabine (1200) Carboplatin

Gemcitabine (1250) Cisplatin

Gemcitabine

Lorlatinib

Nintedanib Docetaxel

Nivolumab

Osimertinib

Pembrolizumab Carboplatin Paclitaxel

Pembrolizumab Pemetrexed Carboplatin without pemetrexed maintenance

Pembrolizumab Pemetrexed Carboplatin

Pembrolizumab Pemetrexed Cisplatin without pemetrexed maintenance

Pembrolizumab Pemetrexed Cisplatin

Pembrolizumab

Pemetrexed Carboplatin

Pemetrexed Cisplatin

Pemetrexed maintenance

Topotecan oral

Vinorelbine (IV) Carboplatin

Vinorelbine (IV) Cisplatin with concurrent RT

Vinorelbine (IV) Cisplatin

Vinorelbine (IV)

Vinorelbine (oral) Carboplatin

Vinorelbine (oral) Cisplatin

Vinorelbine (oral)

Vinorelbine oral Carboplatin RT – Covid 19

For further information please contact us using our contact us page.